지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.6
- 수록면
- 335 - 339 (5page)
이용수
초록· 키워드
오류제보하기
Purpose: Highly sensitized patients with a high level of panel reactive antibody (PRA) experience more episodes of antibody-mediated rejection (AMR) and poorer graft survival than non-sensitized patients. Rituximab is a well-known monoclonal anti-CD20 antibody that causes the depletion of B lymphocytes. The aim of this study was to compare a rituximab-administered and a non-administered group of highly sensitized recipients. Methods: Forty-three kidney recipients with a PRA level of ≥50% were included. Sixteen (group R) received one dose of rituximab at 2 days prior to transplantation and 27 patients (group NR) did not. Results: Patients’ demographics, such as age, sex, dialysis duration, and type of immunosuppressive agent were not different in the two groups. No side effects due to rituximab administration were observed in group R. Class I PRA of group R (75.6 ± 37.7%) was higher than that of group NR (45.7 ± 35.8%, P = 0.013). More acute rejection episodes occurred within 1 year after transplantation in group NR but the difference between the groups was not significant (18.8% in group R vs. 29.6% in group NR, P = 0.631). However, two AMR episodes occurred only in group NR. Renal functions were not different in the two groups. In group R, CD19 and CD20 rapidly decreased 2 days after rituximab infusion. Furthermore, the administration of rituximab was not linked to acute rejection. Conclusion: To confirm the long-term anti-rejection and beneficial effects of rituximab, further studies should be performed with a larger cohort. In conclusion, rituximab administration 2 days prior to transplantation is both effective and safe.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
ACKNOWLEDGEMENTS
REFERENCES
참고문헌 (0)
참고문헌 신청이 논문의 저자 정보
이 논문과 함께 이용한 논문
[Free Paper] Impact of Pretransplant Rituximab Induction on Kidney Graft in Highly Sensitized Recipients
송영해
,
허규하
,
김유선
외 4명
대한외과학회 학술대회 초록집
2011
.11
신장 이식 전 또는 후의 PRA(Panel Reactive Antibody)와 이식편 거부 반응과의 관계
이대성
,
이환효
,
이광웅
외 4명
대한외과학회 학술대회 초록집
2003
.11
타목시펜 내성 유방암세포(T47D:A18/4-OHT)에서 EGFR 및 HER2 억제 효과
원용성
,
주종호
,
김정수
외 5명
Annals of Surgical Treatment and Research
2008
.04
경피적 심낭배액술과 Trastuzumab 단독요법으로 치료한 심낭압전을 동반한 유방암의 심막전이
문형곤
,
정은정
,
박순태
외 7명
Annals of Surgical Treatment and Research
2008
.08
Schedule-dependent synergistic effect of rituximab on the methotrexate chemotherapy against CNS lymphoma
Wonyoung Kang
,
Juyoun Jin
,
Kyeung Min Joo
외 5명
한국실험동물학회 학술발표대회 논문집
2010
.08
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-514-002669225